Synovial-Targeted Biomimetic Nanoparticle: Dual Cytokine Blockade (TNF- α and IL-6) Through Intra-Articular Delivery in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovitis, marked by massive immune-cell infiltration and hyperplasia of the synovial membrane. This leads to irreversible joint destruction, cartilage degradation, bone erosion, severe disability, reduced quality of life, and a substantial socioeconomic burden. The core of this pathology is the overproduction of proinflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), by activated macrophages and fibroblast-like synoviocytes in the inflamed synovium. Biomimetic membrane-coated nanoparticles have emerged as highly promising platforms for the precise targeting of TNF-α and IL-6. By coating synthetic cores with natural cell membranes such as those derived from macrophages, neutrophils, or synovial fibroblasts, these systems enable immune evasion, site-specific inflammatory homing, and dual functionality as cytokine decoys while facilitating controlled intracellular delivery of therapeutics. Compared with conventional therapies, intra-articular administration further enhances their potential by providing direct access to the synovial membrane, prolonging local retention, and minimizing systemic exposure. The preclinical evidence base remains limited — largely single-group, non-replicated studies using CIA models of uncertain human predictive value — and clinical translation faces several major hurdles. Lay Summary Rheumatoid arthritis is a long-term disease causing painful joint inflammation, driven mainly by proteins TNF-α and IL-6. Current drugs target these proteins, but systemic treatments often cause side effects or fail to work for everyone. This review explores a novel approach using biomimetic nanoparticles coated with natural cell membranes to deliver drugs directly into the joint. These cell coatings help nanoparticles target inflamed tissue, avoid immune detection, and neutralize inflammatory proteins locally. While early animal studies are promising, clinical trials in humans are still needed. This localized delivery method could lead to safer, more effective treatments for rheumatoid arthritis. Future Works Description Future research will focus on scaling up standardized, cost-effective manufacturing of membrane-coated nanoparticles while ensuring batch-to-batch consistency. Comprehensive long-term safety, biocompatibility, and pharmacokinetic evaluations in relevant models are required, alongside establishing standardized regulatory frameworks to enable successful translation from preclinical studies to human clinical trials for rheumatoid arthritis.